Array biopharma inc (ARRY)
Income statement / TTM
Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenue

239,573

241,263

200,932

173,768

172,109

139,022

141,327

150,852

160,279

170,046

160,953

137,879

106,994

70,548

62,037

51,909

45,600

46,772

33,919

42,078

61,482

63,664

67,975

69,580

64,828

73,986

78,837

85,135

83,518

82,246

75,519

71,901

0

0

0

Operating expenses
Cost of goods sold

61,397

60,355

59,569

59,374

10,092

17,524

26,550

35,395

30,747

29,162

25,799

23,166

24,699

30,992

38,427

44,392

48,856

47,472

47,484

45,965

41,530

39,398

34,197

30,078

29,332

25,999

24,356

24,261

25,637

26,963

28,079

28,916

0

0

0

Research and development

188,151

193,958

188,167

185,821

219,979

194,700

184,840

178,199

188,605

191,338

186,220

160,655

129,769

92,784

63,250

54,442

50,326

52,640

50,310

49,824

52,162

53,136

57,590

59,420

57,457

58,446

57,655

56,719

61,120

60,909

62,241

63,498

0

0

0

Selling, general and administrative

108,983

90,208

71,342

58,500

51,354

46,295

43,522

39,336

38,975

35,667

36,771

36,267

34,071

33,852

31,992

31,433

28,915

26,133

23,527

21,907

21,289

20,885

20,023

19,624

18,865

17,090

16,262

15,202

15,021

15,590

15,713

16,261

0

0

0

Total operating expenses

358,531

344,521

319,078

303,695

281,425

258,519

254,912

252,930

258,327

256,167

248,790

220,088

188,539

157,628

133,669

130,267

128,097

126,245

121,321

117,696

114,981

113,419

111,810

109,122

105,654

101,535

98,273

96,182

101,778

103,462

106,033

108,675

0

0

0

Gain on the Binimetinib and Encorafenib Agreements, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-118,958

-103,258

-118,146

-129,927

-109,316

-119,497

-113,585

-102,078

-98,048

-86,121

-87,837

-82,209

-79,904

-5,429

10,019

3,293

-2,487

-79,473

-87,402

-75,618

-53,499

-49,755

-43,835

-39,542

-40,826

-27,549

-19,436

-11,047

-18,260

-21,216

-30,514

-36,774

0

0

0

Other income (expense)
Interest income

8,117

6,500

5,469

4,470

3,361

2,294

1,251

796

586

434

273

243

199

138

95

68

52

59

74

77

75

71

60

55

56

46

37

32

36

59

192

406

0

0

0

Interest expense

10,668

10,166

10,181

10,814

11,559

12,293

12,567

12,333

11,963

11,611

11,197

10,874

10,708

10,542

10,394

10,247

10,101

9,959

9,842

9,716

10,048

10,450

10,882

11,258

10,611

10,452

11,428

11,624

12,737

14,231

14,570

15,507

0

0

0

Realized gain from marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Loss on extinguishment and conversion of notes

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Realized gains on investments and other

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of notes payable

-2,252

-2,352

-2,652

-2,387

-700

-1,900

-2,200

-2,600

-2,100

-800

-200

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment loss related to cost method investment

-

-

-

-

-

-

-

1,500

1,500

1,500

1,500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other, net

-54

104

104

69

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense), net

-4,857

-5,914

-13,717

-15,119

-15,174

-17,459

-12,619

-14,740

-14,192

-13,477

-12,624

-10,631

-656

5,851

5,956

6,076

-8,381

-14,634

-14,502

-9,639

-21,932

-22,338

-22,781

-22,400

163

5,652

12,333

12,534

19,041

19,419

18,760

19,550

0

0

0

Net loss

-126,115

-111,472

-134,163

-147,346

-124,490

-136,956

-126,204

-116,818

-112,240

-99,598

-100,461

-92,840

-80,560

422

15,975

9,369

-6,134

-89,373

-97,170

-85,257

-74,669

-71,331

-65,854

-61,942

-52,461

0

0

-

0

-

-49,274

-56,324

0

0

0

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Change in unrealized gain (loss) on marketable securities

922

567

-270

-385

-671

-626

-53

-83

-100

-13

-6

2

-9,784

-13,500

-14,505

3

9,791

13,463

14,514

4

7

0

8

-1

-1

0

1

-4

-1

-4,306

-4,962

-5,525

0

0

0

Comprehensive loss

-125,193

-110,905

-134,433

-147,731

-125,161

-137,582

-126,257

-116,901

-112,340

-99,611

-100,467

-92,838

-90,344

-13,078

1,470

9,372

3,657

-75,910

-82,656

-85,253

-74,662

-71,331

-65,846

-61,943

-52,324

-38,897

-31,768

-23,585

-37,302

-44,941

-54,236

-61,849

0

0

0

Weighted average shares outstanding – basic (in shares)

219,913

215,872

212,193

210,342

208,994

199,852

174,772

170,581

169,020

168,127

145,100

143,469

143,338

142,833

142,216

141,306

139,769

133,815

131,826

-

125,471

-

-

-

-

-

-

-

-

-

-

-

56,129

55,285

53,415

Weighted average shares outstanding – diluted (in shares)

219,913

215,872

212,193

210,342

208,994

199,852

174,772

170,581

169,020

168,127

145,100

143,469

143,338

142,833

142,216

134,862

166,265

133,815

131,826

-

125,471

-

-

-

-

-

-

-

-

-

-

-

56,129

55,285

53,415

Net loss per share – basic (in dollars per share)

-0.17

-0.05

-0.12

-0.24

-0.11

-0.17

-0.22

-0.17

-0.21

-0.14

-0.20

-0.17

-0.16

-0.17

-0.15

-0.08

0.42

-0.06

-0.21

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share – diluted (in dollars per share)

-0.17

-0.05

-0.12

-0.24

-0.11

-0.17

-0.22

-0.17

-0.21

-0.14

-0.20

-0.17

-0.16

-0.17

-0.15

-0.03

0.37

-0.06

-0.21

-

-0.20

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding  basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

123,921

117,509

-

116,665

105,403

92,606

147,597

74,817

60,004

57

-

-

-

-

Net loss per share  basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.13

-0.13

-

-0.19

-0.10

-0.13

-0.10

-0.11

-0.06

-0.06

-0.39

-0.20

-0.23

-0.20

Product sales, net
Revenue

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product royalties
Revenue

0

-

-

-

0

-

-

19,844

15,785

14,977

5,537

3,876

1,962

1,204

20,198

20,367

21,839

26,027

15,215

25,111

47,025

49,586

54,315

56,726

50,962

60,084

65,263

71,249

69,222

67,159

59,095

53,426

0

0

0

Collaboration and license revenue
Revenue

0

0

-

-

0

0

-

23,811

25,722

25,441

26,388

26,673

25,440

25,353

25,196

24,522

22,421

20,745

18,704

16,967

14,457

14,078

13,660

12,854

13,866

13,902

13,574

13,886

14,296

15,087

16,424

18,475

0

0

0

Reimbursement revenue
Revenue

0

0

-

-

0

0

-

107,197

118,772

129,628

129,028

107,330

79,592

43,991

16,643

7,020

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-